Mechanisms of the beneficial effects of vitamin B6 and pyridoxal 5-phosphate on cardiac performance in ischemic heart disease

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 3, 2013, Pages 535-543

  Dhalla, Naranjan S ^b   Takeda, Satoshi ^a,b   Elimban, Vijayan ^b  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Cardiac performance; Ischemia reperfusion injury; Myocardial infarction; Pyridoxal 5 phosphate; Vitamin B6

Indexed keywords

2 METHYLTHIOADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE; C REACTIVE PROTEIN; CALCIUM ION; HOMOCYSTEINE; ISOPRENALINE; KYNURENINE; MRS 2339; PURINERGIC P2 RECEPTOR; PURINERGIC P2X RECEPTOR AGONIST; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAL PHOSPHATE 6 AZOPHENYL 2',4' DISULFONIC ACID; PYRIDOXINE; SURAMIN; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PYRIDOXINE DEFICIENCY;

ANIMALS; CARDIOTONIC AGENTS; HEART; MYOCARDIAL ISCHEMIA; PYRIDOXAL PHOSPHATE; REPERFUSION INJURY; VITAMIN B 6; VITAMIN B 6 DEFICIENCY;

EID: 84882334258     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0553     Document Type: Conference Paper

References (91)

1. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. J Am Med Assoc 2002;287:3116-26.
2. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. J Am Med Assoc 1993;270:2693-8.
3. Rogers KS, Mohan C. Vitamin B6 and diabetes. Biochem Med Metab Biol 1994;52:10-7.
4. Cohen KL, Gorecki G, Silverstein SB, Ebersole JS, Solomon LR. Effect of pyridoxine (vitamin B6) on diabetic patients with peripheral neuropathy. J Am Podiatry Assoc 1984;74:394-7.
5. Ellis JM, Folkers K, Minadeo M, Van Buskirk R, Xia LJ, Tamagawa H. A deficiency of vitamin B6 is a plausible molecular basis of the retinopathy of patients with diabetes mellitus. Biochem Biophys Res Commun 1991;179:615-9.
6. Calvaresi E, Bryan JB. Vitamins, cognition and aging: a review. J Gerontol B Psychol Sci Soc Sci 2001;56:P327-39.
7. Bryan J, Calvaresi E, Hughes D. Short-term folate, vitamin B-12 or vitamin B-6 supplementation slightly affects memory performance but not mood in women of various ages. J Nutr 2002;132:1345-56.
8. Fletcher RH, Fairfield KM. Vitamins for chronic disease prevention in adults: clinical applications. J Am Med Assoc 2002;287:3127-9.
9. Dhalla NS, Sethi R, Dakshinamurti K. Treatment of cardiovascular and related pathologies. US Patent 6, 043, 259, March 28, 2000.
10. Dakshinamurti K, Sethi R, Dhalla NS. Treatment of iatrogenic and age-related hypertension and pharmaceutical composition useful therein, United States Patent Number 6, 051, 587, April 18, 2000.
11. Rhinehart JF, Greenberg LD. Arteriosclerotic lesions in pyridoxine-deficient monkeys. Am J Pathol 1949;25:481-91.
12. Murry JC, Fraser DR, Levine CI. The effect of pyridoxine on lysyl oxidase activity in the chick. Exp Mol Pathol 1978;28:301-8.
13. Tehlivets O. Homocysteine as a risk factor for atherosclerosis: is its conversion to s-adenosyl-L-homocysteine the key to deregulated lipid metabolism. J Lipids 2011;2011:702853.
14. Gopinath B, Flood VM, Rochtchina E, Thiagalingam A, Mitchell P. Serum homocysteine and folate but not vitamin B12 are predicators of CHD mortality in older adults. Eur J Cardiovasc Prevent Rehab 2011;19:1420-9.
15. Washio T, Nomoto K, Watanabe I, Tani S, Nagao K, Hirayama A. Relationship between plasma homocysteine and congestive heart failure in patients with acute myocardial infarction. Homocysteine and congestive heart failure. Int Heart J 2011;52:224-8.
16. Agoston-Coldea L, Mocan T, Gatfosse M, Lupu S, Dumitrascu DL. Plasma homocysteine and the severity of heart failure in patients with previous myocardial infarction. Cardiol J 2011;18:55-62.
17. Ubbink JB, Vermaak WJ, Van Der Merwe A, Becker PJ. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 1993;57:47-53.
18. Herzlich BC. Plasma homocysteine, folate, vitamin B6 and coronary artery disease risk. J Am Coll Nutr 1996;15:109-10.
19. Serfontein WJ, Ubbink JB, De Villiers LS, Rapley CH, Becker PJ. Plasma pyridoxal-5-phosphate level as risk index for coronary artery disease. Atherosclerosis 1985;55:357-61.
20. Kok FJ, Schrijver J, Hofman A, Wittman JC, Kruyssen D, Remme WJ, et al. Low vitamin B6 status in patients with acute myocardial infarction. Am J Cardiol 1989;63:513-6.
21. Ellis JM, McCully KS. Prevention of myocardial infarction by vitamin B6. Res Commun Mol Pathol Pharmacol 1995;89:208-20.
22. Chasan-Taber L, Selhub J, Rosenberg IH, Malinow MR, Terry P, Tishler PV, et al. B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996;15:136-43.
23. Selhub J, Jacques PF, Bostom AG, Wilson PW, Rosenberg IH. Relationship between plasma homocysteine and vitamin status in the Framingham study population. Impact of folic acid fortification. Public Health Rev 2000;28:117-45.
24. Roubenoff R, Roubenoff RA, Selhub J, Nadeau MR, Cannon JG, Freeman LM, et al. Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum 1995;38:105-9.
25. Miller JW, Green R, Mungas DM, Reed BR, Jagust WJ. Homocysteine, vitamin B6, and vascular disease in AD patients. Neurology 2002;58:1471-5.
26. Cabrini L, Bergami R, Florentini D, Marchetti M, Landi L, Tolomelli B. Vitamin B6 deficiency affects antioxidant defences in rat liver and heart. Biochem Mol Biol Int 1998;46:689-97.
27. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B (6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001;103:2788-91.
28. Chen CH, Lin PT, Liaw YP, Ho CC, Tsai TP, Chou MC, et al. Plasma pyridoxal 5'-phosphate and high-sensitivity C-reactive protein are independently associated with an increased risk of coronary artery disease. Nutrition 2008;24:239-44.
29. Midttun O, Ulvik A, Ringdal Pedersen E, Ebbing M, Bleie O, Schartum-Hansen H, et al. Low plasma vitamin B-6 status affects metabolism through the kynurenine pathway in cardiovascular patients with systemic inflammation. J Nutr 2011;141:611-7.
30. Brophy MH, Siiteri PK. Pyridoxal phosphate and hypertensive disorders of pregnancy. Am J Obstet 1975;121:1075-9.
31. Kleiger JA, Altschuler CH, Krakow G, Hollister C. Abnormal pyridoxine metabolism in toxemia of pregnancy. Ann NY Acad Sci 1969;166:288-96.
32. Paulose CS, Dakshinamurti K, Packer S, Stephens NL. Sympathetic stimulation and hypertension in the pyridoxinedeficient adult rat. Hypertension 1988;11:387-91.
33. Lal KJ, Dakshinamurti K, Thilveris J. The effect of vitamin B6 on the systolic blood pressure of rats in various animal models of hypertension. J Hypertens 1996;14:355-63.
34. Viswanathan M, Paulose CS, Lal KJ, Sharma SK, Dakshinamurti K. Alterations in brainstem alpha 2 adrenoreceptor activity in pyridoxine-deficient rat model of hypertension. Neurosci Lett 1990;111:201-5.
35. Lal KJ, Dakshinamurti K. Regulation of calcium influx into vascular smooth muscle by vitamin B6. Clin Exp Hypertens 1993;15:489-500.
36. 2+]i in cardiomyocytes from vitamin B6-deficient rats. Can J Physiol Pharmacol 1998;76:837-42.
37. Kandzari DE, Dery JP, Armstrong PW, Douglas DA, Zettler ME, Hidinger GK, et al. MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs 2005;14:1435-42.
38. Wang CX, Yang T, Noor R, Shuaib A. Role of MC-1 alone and in combination with tissue plasminogen activator in focal ischemic brain injury in rats. J Neurosurg 2005;103:165-9.
39. Kandzari DE, Labinaz M, Cantor WJ, Madan M, Gallup DS, Hasselblad V, et al. Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). Am J Cardiol 2003;92:660-4.
40. Tardif JC, Carrier M, Kandzari DE, Emery R, Cote R, Heinonen T, et al. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg 2007;133:1604-11.
41. Carrier M, Emery R, Kandzari DE, Harrington R, Guertin MC, Tardif JC. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial. J Cardiovasc Surg 2008;49:249-53.
42. Mehta RH, Alexander JH, Emery R, Ellis SJ, Hasselblad V, Khalil A, et al. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II - study design and rationale. Am Heart J 2008;155:600-8.
43. MEND-CABG II Investigators. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial. J Am Med Assoc 2008;299:1777-87.
44. Ren B, Lukas A, Shao Q, Guo M, Takeda N, Aitken RM, et al. Electrocardiographic changes and mortality due to myocardial infarction in rats with or without imidapril treatment. J Cardiovasc Pharmacol Ther 1998;3:11-22.
45. Barta J, Sanganalmath SK, Kumamoto H, Takeda N, Edes I, Dhalla NS. Antiplatelet agents sarpogrelate and cilostazol affect experimentally-induced ventricular arrhythmias and mortality. Cardiovasc Toxicol 2008;8:127-35.
46. Takeda S, Mochizuki S, Saini HK, Elimban V, Dhalla NS. Modification of alterations in cardiac function and sarcoplasmic reticulum by vanadate in ischemic-reperfused rat hearts. J Appl Physiol 2005;99:999-1005.
47. Dhalla NS, Wang X, Beamish RE. Intracellular calcium handling in normal and failing hearts. Exp Clin Cardiol 1996;1:7-20.
48. Lee WM, Elliot JE, Brownsey RW. Inhibition of acetyl-CoA carboxylase isoforms by pyridoxal phosphate. J Biol Chem 2005;280:41835-43.
49. Pham V, Zhang W, Chen V, Whitney T, Yao J, Froese D, et al. Design and synthesis of novel pyridoxine 5'-phosphonates as potential antiischemic agents. J Med Chem 2003;46:3680-7.
50. Kannan K, Jain SK. Effect of vitamin B6 on oxygen radicals, mitochondrial membrane potential, and lipid peroxidation in H 2O2-treated U937 monocytes. Free Radic Biol Med 2004;36:423-8.
51. Cui J, Leuenberger UA, Blaha C, King NC, Sinoway LI. Effect of P2 receptor blockade with pyridoxine on sympathetic response to exercise pressor reflex in humans. J Physiol 2011;589:685-95.
52. Fu LW, Longhurst JC. A new function for ATP: activating cardiac sympathetic afferents during myocardial ischemia. Am J Physiol Heart Circ Physiol 2010;299:H1762-71.
53. Miner SE, Cole DC, Evrovski J, Forrest Q, Hutchison S, Holmes K, et al. Pyridoxine improves endothelial function in cardiac transplant recipients. J Heart Lung Transplant 2001;20:964-9.
54. Lambrecht G, Braun K, Damer M, Ganso M, Hildebrandt C, Ullmann H, et al. Structure-activity relationships of suramin and pyridoxal-5'-phosphate derivatives as P2 receptor antagonists. Curr Pharm Des 2002;8:2371-9.
55. Millart H, Alouane L, Oszust F, Chevallier S, Robinet A. Involvement of P2Y receptors in pyridoxal-5'-phosphate-induced cardiac preconditioning. Fundam Clin Pharmacol 2009;23:279-92.
56. Trezise DJ, Bell NJ, Khakh BS, Michel AD, Humphrey PA. P2 purinoceptor antagonist properties of pyridoxal-5-phosphate. Eur J Pharmacol 1994;259:295-300.
57. Trezise DJ, Kennedy I, Humphrey PA. The use of antagonists to characterize the receptors mediating depolarization of the rat isolated vagus nerve by alpha, beta-methylene adenosine 5'-triphosphate. Br J Pharm 1994;112:282-8.
58. Wang X, Dakshinamurti K, Musat S, Dhalla NS. Pyridoxals'-phosphate is an ATP-receptor antagonist in freshly isolated rat cardiomyocytes. J Mol Cell Cardiol 1999;31:1063-72.
59. Dhalla NS, Elmoselhi AB, Hata T, Makino N. Status of myocardial antioxidants in ischemia-reperfusion injury. Cardiovasc Res 2000;47:446-56.
60. Dhalla NS, Golfman L, Takeda S, Takeda N, Nagano M. Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review. Can J Cardiol 1999;15:587-93.
61. Burstock G. Purinergic nerves. Pharmacol Rev 1972;24:509-81.
62. Clemens MG, Forrester T. Appearance of adenosine triphosphate in the coronary sinus effluent from isolated working rat heart in response to hypoxia. J Physiol 1981;312:143-58.
63. Forrester T, William CA. Release of adenosine triphosphate from isolated adult heart cells in response to hypoxia. J Physiol 1977;268:371-90.
64. 2+ concentration in isolated rat ventricular myocytes. J Physiol 1992;445:369-88.
65. 2+. Am J Physiol Cell Physiol 1989;257:C750-8.
66. 2+ in rat cardiomyocytes. Cardiovasc Pathobiol 1996;1:152-9.
67. Saini HK, Elimban V, Dhalla NS. Attenuation of extracellular ATP response in cardiomyocytes isolated from hearts subjected to ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2005;289:H614-23.
68. Ninomiya H, Otani H, Lu K, Uchiyama T, Kido M, Imamura H. Complementary role of extracellular ATP and adenosine in ischemic preconditioning in the rat heart. Am J Physiol Heart Circ Physiol 2002;282:H1810-20.
69. Garcia-Villalon AL, Monge L, Fernandez N, Salcedo A, Narvaez-Sanchez R, Dieguez G. Coronary response to diadenosine pentaphosphate after ischaemia-reperfusion in the isolated rat heart. Cardiovasc Res 2009;81:336-43.
70. Wang HJ, Li YL, Gao L, Zucker IH, Wang W. Alteration in skeletal muscle afferents in rats with chronic heart failure. J Physiol 2010;588:5033-47.
71. Kindig AE, Hayes SG, Kaufman MP. Purinergic 2 receptor blockade prevents the responses of group IV afferents to post-contraction circulatory occlusion. J Physiol 2007;578:301-8.
72. Dergacheva O, Wang X, Kamendi H, Cheng Q, Pinol RM, Jameson H, et al. 5HT2 receptor activation facilitates P2X receptor mediated excitatory neurotransmission to cardiac vagal neurons in the nucleus ambiguous. Neuropharmacology 2008;54:1095-102.
73. Jameson HS, Pinol RA, Mendelowitz D. Purinergic P2X receptors facilitate inhibitory GABAergic and glycinergic neurotransmission to cardiac vagal neurons in the nucleus ambiguous. Brain Res 2008;1224:53-62.
74. 2+ homeostatis. J Mol Cell Cardiol 2009;47:622-33.
75. 2+-signalling in vascular endothelial cells. Clin Exp Pharmacol Physiol 2003;30:649-52.
76. Shen JB, Cronin C, Sonin D, Joshi BV, Gongora Nieto M, Harrison D, et al. P2X purinergic receptor-mediated ionic current in cardiac myocytes of calsequestrin model of cardiomyopathy: implications for the treatment of heart failure. Am J Physiol Heart Circ Physiol 2007;292:H1077-84.
77. Nakamura T, Iwanaga K, Murata T, Hori M, Ozaki H. ATP induces contraction mediated by the P2Y (2) receptor in rat intestinal subepithelial myofibroblasts. Eur J Pharmacol 2011;657:152-8.
78. Fischer Y, Becker C, Loken C. Purinergic inhibition of glucose transport in cardiomyocytes. J Biol Chem 1999;274:755-61.
79. Anikina TA, Bilalova GA, Zverev AA, Sitdikov FG. Role of P2X and P2Y receptors in rat myocardial contractility during ontogeny. Bull Exp Biol Med 2007;143:695-8.
80. Tanaka N, Nejime N, Kubota Y, Kagota S, Yudo K, Nakamura K, et al. Myosin light chain kinase and Rho-kinase participate in P2Y receptor-mediated acceleration of permeability through the endothelial cell layer. J Pharm Pharmacol 2005;57:335-40.
81. Yao ST, Lawrence AJ. Purinergic modulation of cardiovascular function in the rat locus coeruleus. Br J Pharmacol 2005;145:342-52.
82. Payne SJ, Brown CA, Benjamin IS, Alexander B. Pyridoxalphosphate-6- azophenyl-2, 4-disulphonic acid (PPADS) as a tool for differentiation of P2Y2-receptor-mediated vasorelaxation in guinea pig aorta. Methods Find Exp Clin Pharmacol 2002;24:351-6.
83. Tully DB, Allgood VE, Cidlowski JA. Modulation of steroid receptor-mediated gene expression by vitamin B6. FASEB J 1994;8:343-9.
84. Compton MM, Cidlowski JA. Vitamin B6 and glucocorticoid action. Endocr Rev 1986;7:140-8.
85. Allgood VE, Powell-Oliver FE, Cidlowski JA. The influence of vitamin B6 on the structure and function of the glucocorticoid receptor. Ann NY Acad Sci 1990;585:452-65.
86. Allgood VE, Powell-Oliver FE, Cidlowski JA. Vitamin B6 influences glucocorticoid receptor-dependent gene expression. J Biol Chem 1990;265:12424-33.
87. Allgood VE, Cidlowski JA. Vitamin B6 modulates transcriptional activation by multiple members of the steroid hormone receptor superfamily. J Biol Chem 1992;267:3819-24.
88. Ozyhar A, Kiltz HH, Pongs O. Pyridoxal phosphate inhibits the DNA-binding activity of the ecdysteroid receptor. Eur J Biochem 1990;192:167-74.
89. Okamoto K, Isohashi F, Ueda K, Sakamoto Y. Properties of an adenosine triphosphate-stimulated factor that enhances the nuclear binding of activated glucocorticoid-receptor complex: binding to histone agarose. Endocrinology 1989;124:675-80.
90. Huq MD, Tsai NP, Lin YP, Higgins L, Wei LN. Vitamin B6 conjugation to nuclear corepressor RIP140 and its role in gene regulation. Nat Chem Biol 2007;3:161-5.
91. Bolander FF. Vitamins: not just for enzymes. Curr Opin Invest Drugs 2006;7:912-5.